Clinical Trial Update: Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung [Phase 1]

View source ↗

Summary

Phase 1 trial of erlotinib hydrochloride for prevention of cancer in patients with precancerous lung lesions was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysplasia
• Metaplasia
• Pulmonary Precancerous Condition

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Dysplasia, Metaplasia | Phase 1 | Status: TERMINATED